By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Warnex said this week that the conversion of debentures into shares of the company will provide Persistence Capital Partners with a nearly 52 percent stake in the firm.

The conversion of C$725,000 in principal amount of debentures into an aggregate of 46,178,344 common shares of Warnex was set to take place yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.